Plasma proteomics-based biomarkers for predicting response to mesenchymal stem cell therapy in severe COVID-19.

ABSTRACT:

Background

The objective of this study was to identify potential biomarkers for predicting response to MSC therapy by pre-MSC treatment plasma proteomic profile in severe COVID-19 in order to optimize treatment choice.

Methods

A total of 58 patients selected from our previous RCT cohort were enrolled in this study. MSC responders (n = 35) were defined as whose resolution of lung consolidation ≥ 51.99% (the median value for resolution of lung consolidation) from pre-MSC to 28 days post-MSC treatment, while non-responders (n = 23) were defined as whose resolution of lung consolidation < 51.99%. Plasma before MSC treatment was detected using data-independent acquisition (DIA) proteomics. Multivariate logistic regression analysis was used to identify pre-MSC treatment plasma pro

SUBMITTER: Li TT 

PROVIDER: S-EPMC10712100 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature